Junshi Bio Schedules 2026 Interim Results Briefing for 14 September

Bulletin Express09-04

Shanghai-headquartered biopharmaceutical firm Junshi Bio will hold an online investor briefing on 14 September 2026, from 10:00 a.m. to 11:00 a.m. (Beijing time), to discuss its first-half 2026 operating and financial performance.

The session will be hosted via the Shanghai Stock Exchange (SSE) Roadshow Center, allowing real-time interaction with investors. Shareholders can pre-submit questions through the SSE Roadshow Center’s “Pre-collection of Questions” section or by emailing info@junshipharma.com between 7 September and 16:00 on 11 September.

Expected company representatives include Executive Director, General Manager and CEO Zou Jianjun; Independent Non-Executive Director Li Zhongxian; Financial Director Xu Baohong; and Board Secretary Wang Zhengyu. Attendee lists may change if special circumstances arise.

Junshi Bio released its 2026 interim report on 27 August 2026 via the SSE website, providing details of its financial results for the six months ended 30 June 2026. The upcoming briefing aims to offer deeper insight into these disclosures and address investor concerns within the scope of regulatory guidelines.

The Board affirms the accuracy, completeness and timeliness of the information disclosed and accepts legal responsibility for the announcement’s contents. Investors can review replay materials and key takeaways on the SSE Roadshow Center following the event.

For further inquiries, the company’s Securities Department can be reached at +86 21 6105 8800 ext. 1153 or via the email address above.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104133315?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-04 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104133315","market":"us","top_or_hot":-1,"title":"Junshi Bio Schedules 2026 Interim Results Briefing for 14 September","media":"Bulletin Express","content":"<p>Shanghai-headquartered biopharmaceutical firm Junshi Bio will hold an online investor briefing on 14 September 2026, from 10:00 a.m. to 11:00 a.m. (Beijing time), to discuss its first-half 2026 operating and financial performance.</p>\n<p>The session will be hosted via the Shanghai Stock Exchange (SSE) Roadshow Center, allowing real-time interaction with investors. Shareholders can pre-submit questions through the SSE Roadshow Center’s “Pre-collection of Questions” section or by emailing info@junshipharma.com between 7 September and 16:00 on 11 September.</p>\n<p>Expected company representatives include Executive Director, General Manager and CEO Zou Jianjun; Independent Non-Executive Director Li Zhongxian; Financial Director Xu Baohong; and Board Secretary Wang Zhengyu. Attendee lists may change if special circumstances arise.</p>\n<p>Junshi Bio released its 2026 interim report on 27 August 2026 via the SSE website, providing details of its financial results for the six months ended 30 June 2026. The upcoming briefing aims to offer deeper insight into these disclosures and address investor concerns within the scope of regulatory guidelines.</p>\n<p>The Board affirms the accuracy, completeness and timeliness of the information disclosed and accepts legal responsibility for the announcement’s contents. Investors can review replay materials and key takeaways on the SSE Roadshow Center following the event.</p>\n<p>For further inquiries, the company’s Securities Department can be reached at +86 21 6105 8800 ext. 1153 or via the email address above.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Junshi Bio Schedules 2026 Interim Results Briefing for 14 September</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJunshi Bio Schedules 2026 Interim Results Briefing for 14 September\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-04 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai-headquartered biopharmaceutical firm Junshi Bio will hold an online investor briefing on 14 September 2026, from 10:00 a.m. to 11:00 a.m. (Beijing time), to discuss its first-half 2026 operating and financial performance.</p>\n<p>The session will be hosted via the Shanghai Stock Exchange (SSE) Roadshow Center, allowing real-time interaction with investors. Shareholders can pre-submit questions through the SSE Roadshow Center’s “Pre-collection of Questions” section or by emailing info@junshipharma.com between 7 September and 16:00 on 11 September.</p>\n<p>Expected company representatives include Executive Director, General Manager and CEO Zou Jianjun; Independent Non-Executive Director Li Zhongxian; Financial Director Xu Baohong; and Board Secretary Wang Zhengyu. Attendee lists may change if special circumstances arise.</p>\n<p>Junshi Bio released its 2026 interim report on 27 August 2026 via the SSE website, providing details of its financial results for the six months ended 30 June 2026. The upcoming briefing aims to offer deeper insight into these disclosures and address investor concerns within the scope of regulatory guidelines.</p>\n<p>The Board affirms the accuracy, completeness and timeliness of the information disclosed and accepts legal responsibility for the announcement’s contents. Investors can review replay materials and key takeaways on the SSE Roadshow Center following the event.</p>\n<p>For further inquiries, the company’s Securities Department can be reached at +86 21 6105 8800 ext. 1153 or via the email address above.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1104133315","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104133315","pubTimestamp":1788527157,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai-headquartered biopharmaceutical firm Junshi Bio will hold an online investor briefing on 14 September 2026, from 10:00 a.m. to 11:00 a.m. (Beijing time), to discuss its first-half 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"君实生物定于 9 月 14 日举行 2026 年中期业绩说明会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Shanghai-headquartered biopharmaceutical firm Junshi Bio will hold an online investor briefing on 14 September 2026, from 10:00 a.m. to 11:00 a.m. (Beijing time), to discuss its first-half 2026 operating and financial performance.\nThe session will be hosted via the Shanghai Stock Exchange (SSE) Roadshow Center, allowing real-time interaction with investors. Shareholders can pre-submit questions through the SSE Roadshow Center’s “Pre-collection of Questions” section or by emailing info@junshipharma.com between 7 September and 16:00 on 11 September.\nExpected company representatives include Executive Director, General Manager and CEO Zou Jianjun; Independent Non-Executive Director Li Zhongxian; Financial Director Xu Baohong; and Board Secretary Wang Zhengyu. Attendee lists may change if special circumstances arise.\nJunshi Bio released its 2026 interim report on 27 August 2026 via the SSE website, providing details of its financial results for the six months ended 30 June 2026. The upcoming briefing aims to offer deeper insight into these disclosures and address investor concerns within the scope of regulatory guidelines.\nThe Board affirms the accuracy, completeness and timeliness of the information disclosed and accepts legal responsibility for the announcement’s contents. Investors can review replay materials and key takeaways on the SSE Roadshow Center following the event.\nFor further inquiries, the company’s Securities Department can be reached at +86 21 6105 8800 ext. 1153 or via the email address above.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104133315","isCrawlerRequest":true}